Q-TOF/MS detected results of the Lysostaphin and recombinant Lysostaphin-ELP(V)90

ABSTRACT: This study engineered a recombinant lysostaphin (Lst) variant, Lst-ELP(V)₉₀, as a therapeutic candidate for prosthetic explant biofilm infections caused by methicillin-resistant Staphylococcus aureus (MRSA). Compared with the wild-type (WT) lysostaphin, the recombinant construct exhibited markedly improved stability and attenuated immunogenicity, establishing a robust foundation for downstream drug development.

INSTRUMENT(S):

ORGANISM(S): Escherichia Coli

SUBMITTER: Guoqing Fan  

LAB HEAD: Weiping Gao

PROVIDER: PXD080789 | Pride | 2026-08-13

REPOSITORIES: Pride